A high-throughput assay for tau phosphorylation by cdk5/p25 is described. Full-length recombinant tau was used as a substrate in the presence of saturating adenosine triphosphate (ATP). Using PHF-1, an antibody directed specifically against 2 tau phosphorylation epitopes (serine 396 and serine 404), an enzyme-linked immunosorbent assay (ELISA)-based colorimetric assay was formatted in 384-well plates. The assay was validated by measuring kinetic parameters for cdk5/p25 catalysis and known inhibitors. Rate constants for the site-specific phosphorylations at the PHF-1 epitopes were determined and suggested preferential phosphorylation at these sites. The performance of this assay in a high-throughput format was demonstrated and used to identify inhibitors of tau phosphorylation at specific epitopes phosphorylated by cdk5/p25. (Journal of Biomolecular Screening 2004:122-131) 
INTRODUCTION
A LZHEIMER'S DISEASE (AD) IS THE MOST COMMON type of dementia affecting the elderly. It is characterized by the formation of 2 types of protein aggregates: extracellular amyloid protein deposits as senile plaques and intracellular hyperphosphorylated tau protein deposits as neurofibrillary tangles. 1 Tau is one of several microtubule-associated proteins that regulate the assembly and stabilization of the microtubule network by its microtubulebinding properties. 2 Tau binding to microtubules is regulated by the expression of specific splice isoforms and their phosphorylation state. Phosphorylated tau is important during brain development, possibly to maintain a certain degree of microtubule instability, which affects neurite outgrowth. 3 With maturation, hyperphosphorylated tau is less readily detected. [4] [5] [6] Under a variety of pathological conditions, including Alzheimer's disease, hyperphosphorylated tau self-aggregates into neurofibrillary tangles. In the AD brain, 19 phosphorylation sites have been identi-fied in paired helical filament (PHF) tau throughout its 441 amino acids. 7, 8 In vitro experiments have demonstrated that tau is a substrate for many kinases, including cyclic adenosine 5′monophosphate (cAMP) dependent protein kinase, 9 calcium/ calmodulin-dependent protein kinase, 10 protein kinase C, 11 casein kinase, 12 mitogen-activated protein kinase, 13 microtubule affinityregulating kinase, 14 glycogen synthase kinase, 15 and cyclindependent kinase 5, cdk5. [16] [17] [18] [19] Among these kinases, cdk5-a serine-threonine protein kinase, as well as its cyclin-related activator molecules p35, p39, p25, and p29 20 -has been demonstrated to phosphorylate tau at sites implicated in AD pathology. 21, 22 Among the many sites phosphorylated in PHF tau are serine 396 and serine 404. 23 PHF-1 is a monoclonal antibody 24 directed against the phosphorylated tau epitope formed by serine 396 and serine 404. 8, 25 Mutation studies with human tau indicate that phosphorylation by cdk5 at serine 396 and serine 404 is primarily responsible for the functional loss of tau-mediated tubulin polymerization. 23 These in vitro results suggest a possible role for cdk5/ p25 in the initiation of microtubule destabilization. Therefore, specific inhibitors for tau hyperphosphorylation may be useful agents to treat AD. Several classes of potent inhibitors for cyclindependent kinases (CDK) have been described. These include olomoucine, roscovitine, purvalanol, flavopiridol, butyrolactone, indirubins, hymenialdisine, the paullones, and the aloisines. [26] [27] [28] [29] [30] [31] [32] [33] However, all these inhibitors, except aminothiazole, 33 are competitive inhibitors at the ATP binding site, resulting in a lack of specificity among the many ATP-dependent kinases. [26] [27] [28] [29] [30] [31] [32] [33] The exact mechanism of their cellular effects is poorly understood. Cur-rently, various CDK inhibitors are being evaluated for therapeutic use against cancer, cardiovascular diseases, viral infections, glomerulonephritis, stroke, and neurodegenerative diseases, such as Alzheimer's disease and amyotrophic lateral sclerosis.
Here we report the development of a miniaturized tau phosphorylation assay using cdk5/p25 and the monoclonal antibody PHF-1. This assay was performed in the presence of a high concentration of ATP to identify inhibitors that elicit activity via a non-ATP binding site interaction. Using the assay described, we discovered molecules that inhibit the cdk5/p25-catalyzed phosphorylation of tau at serine 396 and serine 404.
MATERIALS AND METHODS

Preparation of human recombinant tau
Preparation of tau protein was carried out according to the method described by Lee et al. 34 with slight modifications. Briefly, a plasmid encoding the longest human tau cDNA was transformed into BL21 competent cells, following the procedure described in Novagen's pET system manual. After induction of protein expression using isopropyl β-D-thiogalactopyranoside, cell pellets were collected and resuspended in a 3-[N-Morpholino]propanesulfonic acid (MOPS) buffer. The cells were lysed with a Microfluidizer (Technika, Chester, CT). Taking advantage of tau's heat stability, 9 the cell lysate was placed in a boiling water bath for 10 min, and protein aggregates were removed by centrifugation. The recombinant tau was further purified by column chromatography over a MonoS HiTrap (Amersham). The tau protein concentration was measured by BCA (Pierce, Rockford, IL) using bovine serum albumin (BSA) as a standard. The purified tau was stored at -80°C until use.
Preparation of the cdk5 and p25
Sequences encoding p25 and wild-type human cdk5 were individually subcloned into the pFastBac 1 transfer vector (GIBCO-BRL), and then baculovirus expression vectors were generated according to the manufacturer's guidelines. To generate active cdk5/ p25, we initially attempted a simultaneous coinfection of Spodoptera frugiperda 9 (Sf9) cells with the cdk5 and p25 recombinant baculoviruses. Three days postinfection, cells were harvested, resuspended, and lysed, and the resulting lysates were incubated with Ni-NTA beads to isolate the complex through a hexa-histidine tag fused to the C-terminus of cdk5. The yields of active cdk5/p25 complex generated using this strategy were unsatisfactory. This was probably due to cellular toxicity during cdk5/ p25 expression, as inferred from the observation that the yields of cdk5 in the absence of the p25 activator were significantly higher.
As an alternative strategy, we coinfected insect cells with the virus encoding wild-type cdk5 and a previously described dualexpression baculovirus bearing sequences encoding a histidinetagged and inactive version of cdk5 (D144N mutant) and p25. 35 Suspension cultures of Sf9 insect cells were grown to a density of 10 6 cells per mL at 28°C and infected with the 2 recombinant baculoviruses at varying multiplicities of infection to identify the most suitable ratios. Cells were harvested 72 h postinfection by centrifugation at 123 g for 10 min and washed in phosphatebuffered saline. Pelleted Sf9 cells were resuspended in a buffer containing 40 mM Tris-HCl (pH 8), 0.2 M NaCl, 2 mM betamercaptoethanol, 1 mM phenylmethanesulfonyl fluoride, and a tablet of protease inhibitor cocktail (Roche). Cells were lysed by sonication, and the extracts were clarified by centrifugation at 150,000 g for 45 min at 4°C. The supernatant was applied to a 1-mL High Trap metal chelating column (Pharmacia) loaded with NiCl and equilibrated with 40 mM Tris-HCl, 0.2 M NaCl, and 2 mM beta-mercaptoethanol. The column was washed in the equilibration buffer containing 20 mM imidazole in 15 column volumes. The complex cdk5/p25 elutes at about 50 mM imidazole. The peak fractions corresponding to the complex were pooled and loaded onto a Sephadex G-25 desalting column (Pharmacia) to adjust the buffer to 10 mM Tris-HC1 (pH 7.6), 0.2 M NaCl, 5% glycerol, 1 mM ethylenediaminetetraacetic acid (EDTA), and 2 mM dithiothreitol (DTT). The purity of cdk5/p25 was assessed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and the concentration was determined by absorption at 280 nm using an extinction coefficient of 55,900 cm -1 M -1 . The protein preparation was concentrated in a stirred ultrafiltration cell (Amicon) to 2 mg per mL and then flash-frozen in liquid nitrogen. This strategy yielded approximately 10 mg of pure protein from 1 L of suspension culture. The sample contained a combination of inactive and active cdk5 kinase bound to p25, and its specific activity appears to be roughly equal to 50% of pure wild-type complex.
FILTER ASSAY FOR TAU PHOSPHORYLATION
Purified tau (4.9 µg/mL) was incubated with cdk5/p25 (250 ng/ mL) at 30°C for 1 h in a buffer containing 20 mM MOPS (pH 7.4), 5 mM MgCl, 1 mM EDTA, 1 mM DTT, 0.5 mg/mL BSA, 0.5 µCi of [γ-33 P] ATP plus 200 µM unlabeled ATP, and a protease inhibitor cocktail (Roche). At the end of incubation, trichloroacetic acid (Sigma, MO) was added to a final concentration of 20% to terminate the reaction and precipitate proteins. The mixture was then transferred to a Durapore PVDF membrane (Millipore, Billerica, MA). The filters were washed and punched. The radioactivity in the precipitate bound to the filter was counted. From these experiments, optimal reaction times and Km and V max values of the enzyme for substrates were determined. was stored at -80°C until use. The mass-spectrum analysis of biotinylated tau was performed at SynPep Corp (Dubline, CA).
Evaluation of phosphorylation of tau in ELISA format
The assay conditions for phosphorylation of biotinylated tau were very similar to those described in the filter assay without the 33 P-tracer. The reaction was carried out at room temperature for 90 min and terminated by addition of 10 µL of 50 mM EDTA to a final concentration of 10 mM. Then, 40 µL of the reaction mixture was transferred to a 384-well plate coated with streptavidin (Greiner). The plate was incubated at room temperature for an additional 1 h to allow for the capture of the biotinylated tau. The unbound tau was removed by 6 washes of 120 µL each with phosphate-buffered saline with 0.01% Tween-20 (PBST). The PHF-1 antibody was added, and then after a 1-h incubation at room temperature, the plate was washed extensively with 120 µL of PBST each for 6 times. A rabbit antimouse antibody, which was conjugated with horseradish peroxidase (Promega), was used as a reporter. Then, 3, 3′, 5, 5′-tetramethyl benzidine (TMB) was added as a substrate for the peroxidase to develop the color product according to the manufacturer's instruction (PharMingen). The color was quantified using a plate reader (SpectraMaxx 384, Molecular Devices) at 450 nm.
Antibodies
Antihuman tau antibody and antibiotin HRP-linked antibody were purchased from Biosource (Camarillo, CA) and Cell Signaling (Beverly, MA), respectively. A phosphorylation-dependent antitau antibody (PHF-1) was a generous gift from Dr. Peter Davies (Albert Einstein College of Medicine, NY).
WESTERN BLOT ANALYSIS
Equal amounts of recombinant tau and biotinylated tau were fractionated by SDS-PAGE (8%-16% Tris-Glycine Gel, Invitrogen) and transferred to a nitrocellulose membrane (PROTRAN®, Midwest Scientific, Valley Park, MO). The nonspecific binding was blocked by incubating the membranes overnight at 4°C with phosphate-buffered saline (GIBCO) containing 0.01% Tween-20 (PBST) and 5% nonfat milk. Then the membranes were washed with PBST several times. For detection of total native or biotinylated tau, membranes were incubated for 1 h at room temperature with either rabbit polyclonal antihuman tau (1:1000) or antibiotin HRP-linked antibody (1:1000), respectively. Horseradish-conjugated anti-rabbit IgG was used as a reporter antibody following the incubation with the antihuman tau antibody. Then, membranes were incubated with chemiluminescence dye (New England Biolabs, Beverly, MA) for 1 min at room temperature. Blots were exposed to X-ray film (Kodak XAR film) at room temperature. For a Coomassie blue staining, the gel was stained with Coomassie Brilliant Blue (BIO-RAD, Hercules, CA).
High-throughput screening
Compound libraries available for screening consist of FDAapproved drugs, purified compounds from natural sources, peptides, and small molecules purchased from Peakdale, Maybridge, Cerep, Bionet, Prestwick, and SPECS, and Chemical Diversity Lab compounds (0.4 µL of 5 mM) in 100% DMSO solution in the library were spotted onto 384-well polypropylene plates (Greiner) with 12 negative and 20 positive control wells in each plate. The positive controls were incubated with all components except compounds. In each screen, a full plate control was used as quality controls for that screen. The plates containing the spotted compounds were covered with plate sealers and stored at -20°C until the day of screening. After adding 35 µL of the phosphorylation mixture containing cdk5/p25, tau, and cofactors to the well containing prespotted compounds (final concentration, 50 µM), the reaction was started by the addition of 5 µL ATP at a final concentration of 200 µM. For a negative control, H 2 O was added instead of ATP. The plate was incubated for 90 min, and the phosphorylation reaction was terminated by the addition of 10 µL of 50 mM EDTA to a final concentration of 10 mM. The reaction mixture (40 µL) was then transferred to a clear 384-well streptavidin plate (Greiner). After washing the streptavidin plate with PBST 6 times using an automated plate washer, 40 µL of PHF-1 antibody (1:1000 dilution) was added. The plate was then incubated for 60 min. After another washing step with PBST (6 times), 40 µL of mouse-HRP antibody (Promega) was added at a 1:1000 dilution and incubated for 45 min. After removing unbound secondary antibody by aspiration, the plate was washed with PBST (6 times), followed by addition of 40 µL of TMB substrate (PharMingen) for a further 45-min incubation. To stop the reaction, 20 µL of 2N H 2 SO 4 was added. The plate was read at an absorbance of 450 nm using a spectrophotometer (SpectraMaxx 384). Compounds were screened at a final concentration of 50 µM at room temperature. The percentage of activity was defined as the fraction of net activity of each compound after subtraction of the background (negative control without ATP) divided by the net positive control (DMSO control minus background control). The percentage of inhibition is 1 minus percentage of activity. Compounds with greater than 50% inhibition at 50 µM were defined as "hits."
RESULTS
Biotinylation of tau
Biotinylated tau was analyzed by SDS gel electrophoresis and Western blot using antibodies against biotin and tau, as shown in Figure 1 . The biotinylated tau migrated more slowly compared with the native tau in the SDS gel, as expected. There are 44 lysines present in human tau. The number of biotin per mole of tau was determined to be 8.6 by mass spectrometry analysis (SynPep Corp., Dublin, CA). To verify that biotinylation did not change the characteristics of tau as a cdk5/p25 substrate, the phosphorylation of biotinylated tau was compared with native tau, using a filter method as shown in Figure 2 . Similar substrate kinetics were obtained, indicating that the binding affinity of tau to the kinase was not affected by limited biotinylation. However, overbiotinylation generated inactive tau for kinase (data not shown). Because phosphorylation substrates for cdk5 require basic amino residues (arginine/lysine) adjacent to the threonine and serine sites, excessive biotinylation may abolish this substrate requirement.
Determination of tau-binding capacity
When the assay was performed in an enzyme-linked immunosorbent assay (ELISA) format, the coating capacity was determined in a separate experiment. Different amounts of tau were incubated with cdk5/p25 for 1.5 h at room temperature before being transferred onto a streptavidin-coated plate. An antibody against total tau is used to assess the binding capacity of the plate (Fig. 3) . The binding capacity reached 80% of the well capacity when 3 pmoles of tau with a final concentration of 0.094 µM were added to each well. When a PHF-1 antibody was used as a probe, a similar binding capacity was found ( Fig. 3) . When 3 pmoles of tau were loaded onto each well, less than 10% of the 3 pmoles (~0.3 pmole) were captured in the well estimated by Western blot (data not shown). The low percentage of capture is expected because the maximum binding capacity of these plates is 4 pmoles per well, as measured by 3 H-biotin binding from the manufacturer's quality control (QC) data. The biotin has a molecular mass of 226, and biotinylated tau has a molecular mass of 48,000. The steric hindrance of the large molecule or the charge interaction, as well as the capture efficiency of biotinylated protein or peptides on the plate, can only reach a fraction of its well capacity. In this calculation, the concentration of tau immobilized on the well is only 7. 
Cdk5/p25-dependent phosphorylation
In both the filter assay and ELISA assay, tau phosphorylation is dependent on the concentration of cdk5/p25, as illustrated in Figure 4A,B . In both experiments, the concentration of tau was 94 nM. The phosphorylation of tau was proportional to the concentration of cdk5/p25, ranging from 50 ng/mL to 250 ng/mL (Fig.  4A,B) .
Substrate-dependent phosphorylation
The phosphorylation of tau by cdk5/p25 exhibited dose dependence for both substrates, ATP and tau, in the filter assay (Fig.  5A,B ). Analysis of these data yielded a Km of 4 µM for tau and 35 µM for ATP, which are similar to the reported values. 36 The recovery of this filter assay was determined to be 36% by using 125 Iprotein. Different concentrations of tau were then incubated with the kinase, and the reaction was terminated with EDTA. Each reaction mixture was then diluted to a final tau concentration of 0.094 µM. Then, 40 µL of the tau (total 3 pmoles) was loaded into each well followed by the addition of PHF-1 antibody and then the reporter antibody. The total activity at each concentration was then calculated according to each dilution factor. The Km for ATP obtained from this method was 11µM, in agreement with the Km derived from the filter assay (Fig. 6A) . Unexpectedly, the Km for tau derived from the average of 3 experiments was 0.4 µM, which is 10-fold lower than the one obtained in the filter assay (Fig. 6B ). This discrepancy might be explained by the fact that the 2 sites (serine 396 and serine 404) that are detected by the specific antibody at these epitopes are more favorable phosphorylation sites for cdk5/p25 compared with other phosphorylation sites, as measured by total 33 P incorporation.
Time-dependent phosphorylation of tau by cdk5/p25
A total of 0.094 µM tau was incubated with 200 µM of ATP in the presence of 5 µCi of 33 P-ATP per assay at 30°C for various time periods, and the reaction was terminated by the addition of trichloroacetic acid. The 33 P incorporation into tau was time dependent up to 4 h (Fig. 7A) . The total number of phosphate incorporated into each molecule of tau at a 60-min incubation was calculated to be 0.97 mole, using the specific activity of 33 P-ATP, the amount of tau, and the recovery of the filter assay. The number of phosphates incorporated into each molecule of tau increased to 3.3 at a 240min incubation. An identical experiment was performed with an ELISA format (Fig. 7B) . The accumulation of product appeared to plateau at 60 min. Because the concentration of phosphorylated tau captured in the well cannot exceed 25 nM and the Kd for the PHF-1 is around 157 nM (data not shown), it is unlikely that the plateau of activity is due to the limitation of antibody binding. It is possible that the difference in time-dependent phosphorylation indicated that the 2 epitopes of serine 396 and serine 404 are more reactive sites for cdk5/p25 compared to other phosphorylation sites, which are detected by 33 P incorporation. Another possibility for the plateau of activity at a 60-min incubation in the ELISA format could be due to the depletion of tau epitopes at serine 396/404 under this condition.
Assay optimization
The assay optimization was carried out by using different concentrations of the primary antibody (PHF-1) and the reporter antibody (mouse-HRP) in the presence of different concentrations of biotinylated tau. The results of this matrix experiment are illustrated in Figure 8A -D. The optimal conditions for the ELISA were found at a dilution factor for a PHF-1 antibody of 1000:1 and a reporter antibody of 1000:1.
Assay validation
To validate the colorimetric ELISA assay of tau phosphorylation by cdk5/p25 using the PHF-1 antibody, a known inhibitor for cdk5, olomoucine, was used. Because olomoucine is a competitive inhibitor for ATP, 37 the assay was modified by lowering the ATP concentration from 200 to 15 µM. As shown in Figure  9 , olomoucine inhibits the phosphorylation of tau in a dosedependent manner and yields an IC 50 of 5 µM, which is similar to the reported value of 3 µM. 37 The inactive isomer of olomoucine (iso-olomoucine) had no activity in this assay, as expected. These results further validate this assay format of cdk5/p25 phosphorylation.
High-throughput screening and assay performance
A chemical library consisting of 12,672 compounds was screened with this kinase assay at a dose of 50 µM in singlet. These 38 Furthermore, they were chosen for the following additional properties: low proportion of compounds that contain known toxicophores, low proportion of compounds that contain reactive functional groups, and maximization of molecular diversity. The high-throughput screening was carried out in a fully automated mode using a Beckman Sagian Core system that consisted of a Biomek Fx pipette station, plate carousel, plate shaker, plate washer, and Cytomate incubator with temperature control from 15 to 50°C. The screening results are expressed as a percentage of inhibition, as illustrated in a scatter diagram shown in Figure 10 . This scatter gram contains data from 4 separate screens performed on 4 different days. The vehicle control groups contained DMSO (1%) in each plate, and a full plate of control for each screen had Z′ values ranging from 0.78 to 0.82. Compounds with greater than 50% inhibition at 50 µM were defined as hits. The replication rate was greater than 85% in duplicate plates containing compounds. The primary hit rate was 0.7%. The confirmation rate in repeated follow-up assays was 60% to 70%. The IC 50 values for active compounds were 0.8 to 50 µM. Hits dereplications are currently under way.
DISCUSSION
CDK inhibitors have been postulated to have therapeutic value in cancer and Alzheimer's disease. Numerous potent chemical inhibitors of CDKs have been reviewed. 39 These include olomoucine, roscovitine, purvalanol, flavopiridol, butyrolactone, indirubins, hymenialdisine, paullones, and the recently described aloisines. [26] [27] [28] [29] [30] [31] [32] Hymenialdisine inhibits in vivo phosphorylation of tau at AD-specific sites in cultured insect cells. 40 Alsterpaullone, a selective inhibitor for cdk5 and glycogen synthase kinase, inhibits the in vivo phosphorylation of tau at AD-specific sites in slices from mouse striatum. 31 Some of the inhibitors have been co-crystallized with cdk2. Most of the potent inhibitors mentioned above are competitive inhibitors for the ATP binding site in cdk5. Affinity gels containing covalently linked inhibitors have been developed to isolate intracellular targets. 26 These efforts have led to the identification of additional targets of CDK inhibitors, such as extracellular signal-regulated kinase (ERK1, ERK2), mitochondrial malate dehydrogenase, glycogen phosphorylase, and cytosolic aldehyde dehydrogenases. These findings suggest that currently known CDK inhibitors may have unwanted side effects in a clinical setting.
In this study, an attempt was made to discover specific inhibitors that might disrupt the interaction of tau and cdk5/p25 at the protein binding sites, rather than the ATP binding site. This approach might lead to the discovery of site-specific inhibitors for tau and cdk5/p25 interactions rather than competitive inhibitors for ATP binding. The recent discovery of aminothiazole inhibitors of cyclin-dependent kinase (cdc2/cyclin E kinase) used a similar approach, with a high concentration of ATP in the assay. 33 Because tau phosphorylation is highly regulated during developmental and adult stages of life, it is important to design specific inhibitors that only inhibit the phosphorylation sites responsible for the pathology of AD. In this study, a robust, high-throughput, miniaturized ELISA was formatted using recombinant tau and cdk5/p25 in the presence of a high concentration of ATP. Furthermore, the assay employs a specific monoclonal antibody that recognizes tau phosphorylation at serine 396 and serine 404. These 2 sites are believed to be involved in microtubule binding and AD pathology. The Km for tau phosphorylation detected by PHF-1 for cdk5/p25 is 10-fold lower as compared with total phosphate incorporation detected by the radioactive 33 
